meningococcal group-B vaccine (rDNA, component, adsorbed): clinical use

Prescribing considerations

• Use should follow current official immunisation recommendations and consider local antigen epidemiology.
• Postpone during an acute severe febrile illness; a minor afebrile infection is not usually a reason to defer.
• Have anaphylaxis treatment available and measures in place to prevent injury from syncope.
• Consider injection-related bleeding risk in thrombocytopenia, coagulation disorders, or anticoagulation.
• Immune response may be reduced by immunosuppression; vaccination does not remove excess risk associated with complement deficiency or terminal complement inhibition.
• Consider respiratory monitoring after primary immunisation in very premature infants, particularly those with respiratory immaturity.
• Clinical data are absent above 50 years and limited in chronic medical conditions.
• Kanamycin is used early in manufacture and may remain at trace levels; safe use in kanamycin-sensitive people is not established.

Contraindications and cautions

• Hypersensitivity to the active substances or any excipient.
• A confirmed anaphylactic reaction to a previous dose or vaccine constituent.

Monitoring

• Observe for immediate allergic or vasovagal reactions after injection.
• Record the product name and batch number for traceability.
• Advise about expected local reactions and fever, and when urgent assessment is needed.
• For very premature infants, consider respiratory monitoring because of possible apnoea.

Clinical pharmacology

The NHBA, NadA, fHbp and PorA-containing outer-membrane components induce bactericidal antibodies. Susceptibility varies with antigen expression, so strain coverage is broad but incomplete; pharmacokinetic assessment is not applicable to vaccines.

Formulation and product differences

• The selected product is a white opalescent suspension supplied in a pre-filled syringe, with packs available with or without needles.
• A fine off-white deposit may form during storage; shake well to produce a homogeneous suspension and inspect before administration.
• Store refrigerated, protect from light, and do not freeze.
• The syringe tip cap and plunger stopper use synthetic rubber. The vaccine contains no thiomersal or porcine gelatine.